During antibody discovery, researchers characterize and optimize thousands of antibody molecules to select ideal drug candidates. Artificial intelligence/machine learning (AI/ML) technologies provide new opportunities for identifying and generating high-quality antibody drugs in less time.
In this webinar brought to you by Integrated DNA Technologies, Charbel Eid, from BigHat Biosciences, will discuss an innovative AI/ML platform that guides antibody design and accelerates the discovery of better antibody therapeutics.
Join this webinar to explore:
For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Head of Platform Development, BigHat Biosciences
Charbel is a leader in life sciences R&D with over ten years of experience blending engineering, science, and technology to solve big problems in life sciences and biomedicine. Charbel currently serves as the Head of Platform Development at BigHat, leading the growth and expansion of BigHat's Milliner platform. Before joining BigHat, Charbel was Manager of Technology Development at Guardant Health and Head of Lab Technology at Driver. Charbel holds a Ph.D. and M.S. from Stanford University (Lieberman Fellow), specializing in microfluidic assay development, and a B.S. from Carnegie Mellon University.